|
INTERxVENT
CORPORATE INFORMATION
INTERxVENTUSA Inc., MAJOR ACCOMPLISHMENTS
THROUGH FEBRUARY 2001
INTERxVENTUSA
Inc.,
founded in July 1997 by Neil F.
Gordon, MD, PhD, MPH, is a Savannah -
based corporation that develops,
tests, implements and licenses
scientifically-based, turn-key
programs for the prevention of
cardiovascular and other chronic
diseases.
The company's mission is to
optimize the health and quality of
life of as many individuals as
possible by providing affordable
access to evidence-based,
comprehensive chronic disease
prevention programs.
Major accomplishments through
February 2001 include:
Tested Products
and Services
Brief
Update
– Nearly 20 years of research and
development have been invested in the
INTERxVENTUSA
products and services.
INTERxVENTUSA
has
developed novel ways, including the
use of handheld computers, to
efficiently screen large populations
and simultaneously integrate
information into its existing
database.
INTERxVENTUSA
has
filed for patents associated with
multiple software applications. These include INTERxVENTUSA's
proprietary
computerized
participant management and tracking
database and outcomes analysis system
that allows for integration and
analysis of up to 255 comprehensive
standalone database applications.
INTERxVENTUSA has
completed phase one of its website
development.
Phase two is ninety percent
complete and phase three has been
specified and planned.
These phases include
integration of INTERxVENTUSA’s
existing network to rapidly facilitate
enterprise wide (global)
accessibility, delivery, and
implementation of services.
Joint Venture
with St. Joseph’s/Candler Health
System
Brief
Update
– In February 1998, INTERxVENTUSA
and St. Joseph’s/Candler Health
System formed an exclusive affiliation
in the Savannah service area and a new
entity was established – INTERxVENT
Savannah, LLC.
INTERxVENT Savannah,
LLC, has programs operating at nine
sites in Savannah – a shopping mall,
St. Joseph’s Hospital, Candler
Hospital and six YMCA's of Coastal
Georgia.
Leading by example, the St.
Joseph’s/Candler Health System is
providing INTERxVENTUSA
as a benefit to its employees enrolled
on the health care plan.
The INTERxVENTUSA
products
and services are now being provided to
many of Savannah's other large
employers, including the City of
Savannah, Chatham County, Georgia
Ports Authority and Interstate Paper.
The INTERxVENTUSA
cardiac rehabilitation product, INTERxVENTCR,
is also being delivered to
participants in the St.
Joseph's/Candler Health System's
cardiac rehabilitation program.
License
Agreement with Neurological Institute
of Savannah
Brief
Update
– The company has executed a license
agreement for a disease management
version of INTERxVENTUSA,
a stroke risk reduction program, for
use with patients in a large neurology
practice.
The INTERxVENTUSA
Stroke
Risk Reduction Program at the
Neurological Institute of Savannah was
successfully implemented in February
1999.
Outcomes analyses documenting
the Program's clinical effectiveness
were presented at the American Heart
Association's annual scientific
meeting in November 2000 and at the
American Stroke Association's
international stroke meeting in
February 2001.
Patients are participating in
the INTERxVENTUSA
Stroke Risk Reduction Program at the
Neurological Institute of Savannah in
two locations, one in
Savannah and a second in
Waycross, Georgia.
Joint Venture
with Emory HealthCare
Brief
Update
– After an extensive due diligence
process by both parties, an exclusive
joint venture relationship was
established with Emory HealthCare for
metropolitan Atlanta and the State of
Georgia in August 1999.
The Emory Hospital cardiology
program has been recognized as one of
the top ten programs by U.S.
News and World Report every year
since the magazine began ranking
hospitals in 1990.
This year, Emory was the only
Georgia hospital and one of just two
in the southeast to be ranked in the
top 10 in cardiology.
Emory HealthCare is committed
to market INTERxVENTUSA
through its primary care physicians,
clinical cardiologists, emergency room
physicians, occupational medicine
programs, and employer contracts
within the Emory HealthCare service
area.
INTERxVENTUSA
programs are currently being delivered
at the Emory Heart Center and at a
major Atlanta-based Fortune 500
company (namely, UPS). INTERxVENTCR is also being
delivered in the cardiac
rehabilitation program at Emory
HealthCare.
Implementation sites for 2001
include the Emory Clinic at Perimeter
Mall, Crawford Long Hospital (downtown
Atlanta), the Blomeyer Health Club on
the Emory University campus, and the
Turner (CNN) Center.
Program expansion activities
includes Diabetes Management and
integration with Executive Health
Services.
Over 1,200 Emory Clinic
physicians are members of the INTERxVENTMD
Network
License
Agreement with North Broward Hospital
District, Fort Lauderdale, Florida
Brief
Update –
In August 1999 the company executed a
license agreement for the INTERxVENTUSA
programs for use with North Broward
Hospital District employees
(approximately 5,000 employees)
covered on its self-insured health
plan and patients in its cardiac
rehabilitation programs.
The district is currently
delivering and expanding the INTERxVENTUSA
programs through its five county
hospitals, which serve a trade area of
two million people.
Effective August 2000, the
district reviewed and expanded its
licenses and added the rights to use
the INTERXVENTUSA
retail product and the INTERxVENTUSA
physician network.
License
Agreements with Other Credible,
Leading Medical Organizations
Brief
Update -
INTERxVENTUSA
has
also executed license agreements with
other prestigious academic/ medical
institutions including Vanderbilt
University (Nashville, TN); the
Medical College of Ohio (Toledo, OH);
William Beaumont Hospital (Detroit,
MI); Trident Health Systems (HCA,
Charleston, SC); North Central CareNet,
Ltd. (Norwalk, OH); Holy Name Hospital
(Teaneck, NJ); Providence Hospital (a
unit of Ascension Healthcare) (Mobile,
AL); a private entrepreneur in the
Hudson Valley, New York area;
and Texas Health System for
seven of its hospitals –
Presbyterian Hospital of Dallas,
Harris Methodist Hospital-Forth Worth,
Presbyterian Hospital of Plano, Harris
Methodist HEB Hospital, Harris
Methodist Northwest Hospital,
McCuistion Regional Medical Center,
and Arlington Memorial Hospital
(Dallas, TX).
Creation and
Implementation of the INTERxVENTMD
Network
Brief
Update
– In order to narrow the gap between
evidence-based medical practice and
actual medical practice, a specific
model for including physicians in a
prevention oriented, national network
has been developed.
The Network product provides
physicians with easy access for their
patients to the INTERxVENTUSA
programs in a way which enables them
to derive revenue for services that
are typically not reimbursable.
The Network product has
received a favorable review and
Advisory Opinion letter from the
Office of Inspector General,
Department of Health & Human
Services.
The Advisory Opinion letter was
issued toward the end of June 2000.
To date, over 100 physicians
have joined the network in the
Savannah service area and the INTERxVENTMD
Network product has been
implemented at their practices.
Attorneys representing Emory
HealthCare have now provided their
approval for the implementation of the
INTERxVENTMD Network
in the Atlanta service area.
A single agreement has been
executed that covers over 1,250
physicians in Atlanta with the Emory
Clinic.
Scientific
Papers and Publications
Brief
Update
– INTERxVENTUSA
is based on models shown to be
effective in randomized clinical
trials.
Moreover, because the data on
all participants in the INTERxVENTUSA
programs is computerized, we have been
able to utilize our proprietary
outcomes analysis software to document
the clinical effectiveness of our
products and services.
Additionally, we have conducted
randomized clinical trials to further
validate the clinical effectiveness of
the INTERxVENTUSA
programs in a variety of patient
populations. Data on the effect of
INTERxVENTUSA on
specific important health risk factors
have been published in the American
Journal of Cardiology, Journal of the
American College of Cardiology,
Circulation, Coronary Artery Disease,
American College of Sports Medicine
Certified News, Medicine and Science
in Sports and Exercise, and the
Journal of Cardiopulmonary
Rehabilitation.
Results have been presented at
the annual scientific meetings of the
American Heart Association, American
College of Cardiology, American
Association of Cardiovascular and
Pulmonary Rehabilitation, American
College of Sports Medicine, and the
American Neurology Association. Collectively, these studies have culminated in an
evidence-based product that has been
enthusiastically embraced by
mainstream medical leaders.
Future research efforts are
being guided by INTERxVENTUSA
staff in consultation with a
prestigious Scientific Advisory
Committee comprised of these leading
academicians / clinicians /
scientists:
Dr. Wayne Alexander, Emory
University Hospital; Dr. Barry A.
Franklin, William Beaumont Hospital;
Dr. William L. Haskell, Stanford
Center for Research in Disease
Prevention; Dr. Harold W. Kohl, The
International Life Sciences Institute;
Dr. Penny M. Kris-Etherton, Penn State
University; Dr. Bess Marcus, Miriam
Hospital; Dr. David Maron, Vanderbilt
Page-Campbell Heart Institute; and Dr.
Kenneth R. Pelletier, Stanford
University.
Special
Projects
Brief
Update
– The credibility and potential importance of the INTERxVENTUSA
programs is best attested to by the
award by the American Heart
Association to Dr. Gordon and the St.
Joseph’s/Candler Health System of a
$499,120 grant to further study the
benefits of the program in patients
with coronary artery disease.
Data from this study,
documenting the clinical- and
cost-effectiveness of the INTERxVENTUSA
program in this specific patient
population, were presented at the
American Heart Association's annual
scientific meeting in November, 2000.
These data clearly demonstrate
that INTERxVENTUSA
programs can be used to increase
accessibility to evidence-based risk
reduction services and have major
implications for cost containment in
cardiovascular medicine.
INTERxVENTUSA
products are also the lifestyle
intervention and compliance tracking
mechanism for a research study
entitled “Implementation of a
Comprehensive Cardiovascular Risk
Reduction Program in Transplant
Recipients” ($427,000 grant from the
Carlos and Marguerite Mason Trust to
St. Joseph’s/Candler Health System,
Neil F. Gordon, MD, principal
investigator).
Additionally, formal, strategic
projects are in progress with several
leading pharmaceutical companies.
Health Claims
Analyses
Data
from randomized clinical trials
conducted using the INTERxVENTUSA
programs and the analyses performed on
data from participants in the INTERxVENTUSA
programs have consistently documented
substantial improvements in multiple
risk factors for cardiovascular
disease and certain other chronic
illnesses, functional capacity, and
various indexes of wellbeing and
quality of life.
Based on data previously
published by other researchers, these
findings would be expected to result
in a reduction in direct and indirect
(for example, due to reduced
productivity and time away from work)
healthcare related expenditures.
As the number of participants
in the INTERxVENTUSA
programs increases over time, it is
anticipated that INTERxVENTUSA
will be able to accurately document
the impact of its programs on
healthcare-related expenditures.
Currently, data are available
for the employees of a Florida-based
company.
Healthcare claims data are
available for 3,062 employees who were
employed by the Florida-based company
in 1999 (the year prior to
implementation of the INTERxVENTUSA
program for the company's employees)
and 2000 (the year the INTERxVENTUSA
program was first implemented).
Of these employees, 636
enrolled in the INTERxVENTUSA
program between February 1 and July
31, 2000.
A comparison was made of the
average healthcare claims per employee
during February 1 through July 31,
1999 and February 1 through July 31,
2000 for INTERxVENTUSA
program participants and
non-participants.
When comparing the 1999 data to
the 2000 data, the average six-month
healthcare claims per employee
increased by 10.3% (or US$110.63) for
the non-participants and decreased by
14.3% (or US$142.47) for the
participants.
This represents an annualized
difference in claims cost of US$500
per participant.
These early data support the
INTERxVENTUSA's
belief that the well-documented
benefits of the INTERxVENTUSA
programs in terms of clinical results
are likely to be accompanied by
reductions in healthcare expenditures.
MEET OUR
EXECUTIVE STAFF
To
contact us for more information on our programs, click
here.
|
